Core Viewpoint - Yiling Pharmaceutical (002603) has received approval from the National Medical Products Administration for the clinical trial of G201-Na capsules, a GnRH receptor antagonist aimed at controlling ovarian hyperstimulation in assisted reproductive technology [1] Group 1 - The clinical trial approval was granted on July 7, 2025 [1] - G201-Na capsules are designed to prevent premature ovulation in patients undergoing controlled ovarian hyperstimulation [1]